doi: 10.1161/JAHA.122.025551. Online ahead of print. 1 Cicarrone Center for the Prevention of Cardiovascular Disease Johns Hopkins University School of Medicine Baltimore MD. 2 Amgen Ltd Cambridge UK. 3 Amgen (Europe) GmbH Rotkreuz Switzerland. 4 Amgen Inc Thousand Oaks CA. 5 University of Glasgow United Kingdom.
Conclusions: Evolocumab, 140 mg Q2W/420 mg once a month, and alirocumab, 150 mg Q2W, were consistently the most efficacious nonstatin regimens when added to maximally tolerated statins to lower LDL‐C, non–high‐density lipoprotein cholesterol, and apolipoprotein B levels and facilitate attainment of guideline‐recommended risk‐stratified lipoprotein levels.